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In-silico study was performed to find the pharmacodynamics, toxicity profiles and biological activities of 
three phytochemicals isolated from Limoniastrum feei (Plumbagenaceae). Online pharmacokinetic tools 
were used to estimate the potential of Quercetin, kaempferol-3-O-β-D-glucopyranoside (astragalin) and 
quercitin-7-O-β-D-glucopyranoside as specific drugs. Then the prediction of potential targets of these 
compounds were investigated using PharmMapper. Auto-Dock 4.0 software was used to investigate the 
different interactions of these compounds with the targets predicted earlier. The permeability of quercetin 
was found within the range stated by Lipinski ׳s rule of five. Hematopoietic prostaglandin (PG) D 
synthase (HPGDS), farnesyl diphosphate synthetase (FPPS) and the deoxycytidine kinase (DCK) were 
potential targets for quercetin, astragalin and quercetin 7, respectively. Quercetin showed antiallergic and 
anti-inflammatory activity, while astragalin and quercetin 7 were predicted to have anticancer activities. 
The activity of Astragalin appeared to be mediated by FPPS inhibition. The inhibition of DCK was 
predicted as the anticancer mechanisms of quercetin 7. The compounds showed interesting interactions 
and satisfactory binding energies when docked into their targets. These compounds are proposed to 
have activities against a variety of human aliments such as allergy, tumors, muscular dystrophy, and 
diabetic cataracts. 
Keywords: Limoniastrum feei/pharmacokinetics. Limoniastrum feei/biological activity. Quercetin. 
Astragalin. Quercetin 7. Medicinal plants. Molecular docking.
INTRODUCTION 
Nowadays, the world of pharmaceutical industry is 
inclining towards finding new chemical entities of natural 
source with biological activities (Neamati, Barchi, 2002). 
Therefore, the identification of different lead compounds 
follow many approaches (Sams-Dodd, 2006), recently, 
the utilization of in silico approach was found cost and 
time effective especially that several regulations and 
standardizations are under way (Pakomwit et al., 2015). 
The proper pharmacokinetics and toxicity profile along 
with efficacy are the major determinants for successful 
drug development. Hence, the poor ADMET profile and 
the risk of toxicity are the major cause of late costly failure 
of drug development. Therefore, these fundamental criteria 
have to be studied carefully at the beginning of the chain of 
drug discovery (Chuai, 2017; Van de Waterbeemd, Gifford, 
2003). In an aim to achieve reliable results, a number of 
tools were developed (Moroy et al., 2012; Gabrielle et al., 
2014). The high cost and lengthy time needed to conduct 
these in vitro screens have called for the development of 
in silico approaches. Computational docking as a means 
to prioritize small molecules in drug discovery projects 
remains a highly popular in silico screening approach. 
Contemporary docking approaches without experimental 
parametrization can reliably differentiate active and 
inactive chemo types in a protein binding site (Pakomwit 
et al., 2015, Van de Waterbeemd, Gifford, 2003). The 
diversity of content in natural plants and the presumably 
safe chemical nature of most of them placed their research 
in the core of drug discovery process. Many plants have 
their ethno medical uses, however many other curative 
potentials of those same plants remain unraveled. Herein, 
the medicinal plant Limoniastrum feei (plumbagenaceae) 
is not an exception. It is a Saharan medicinal plant, used 
in Saharan ethnopharmacopeae to treat gastric tract, 
hepatic disorder and cough (Rahmani et al., 2012). Being 
involved in drug discovery from natural resources, a team 
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of researchers from Algeria has recently isolated and 
identified three antimicrobial phytochemicals namely, 
quercetin 1, kaempferol-3-O-β-D-glucopyranoside 2 
(astragalin) and quercetin-7-O-β-D-glucopyranoside 3 
(quercetin 7) (Ziane et al., 2015). Their chemical structures 
are displayed in Figure 1. To further estimate the drug 
ability of these phytochemicals, we herein report their 
ADMET profiles and potential biological activities using 
several in silico approaches.
MATERIALAND METHODS 
Generation of the chemical structures
To estimate the in silico pharmacokinetic parameters 
of each one of the compounds, some web based in silico 
pharmacokinetic tools were used by submitting the 
chemical structure in the form of canonical simplified 
molecular input line entry system (SMILE).
1. Quercetin: C1=CC(=C(C=C1C2=C(C(=O)C3=C(-
C=C(C=C3O2)O)O)O)O)O
2. Kaempferol-3-O-β-D-glucopyranoside (astragalin): 
C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=-
C3O2)O)O)OC4C(C(C(C(O4)CO)O)O)O)O
3. Quercetin-7-O-β-D-glucopyranoside: C1=CC(=C(-
C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)OC4C(-
C(C(C(O4)CO)O)O)O)O)O)O)O
Molecular parameters 
The estimation of the molecular parameters of the 
three lead compounds was performed using Molinspiration 
online server (http://www.molinspiration.com/). The 
estimated molecular properties were LogP, Topological 
polar surface area (TPSA), the number of hydrogen bond 
donors (HBD) and hydrogen bond acceptors (HBA). 
Drug likeliness property of the tested molecules was 
investigated as Gprotein coupled receptor (GPCR) ligands, 
ion channel modulators (ICM), kinase inhibitors (KI), 
nuclear receptor ligands (NRL), protease inhibitors (PI) 
and enzyme inhibitors (EI). 
Admet properties 
The ADMET profiles of the lead Chemicals were 
predicted using Admet SAR online server (http://lmmd.
ecust.edu.cn:8000/) (Cheng et al., 2012).
Metabolic transformations 
The metabolic transformations of the three 
compounds were obtained using MetaPrint2D online 
server (http://www-metaprint2d.ch. cam.ac.uk/) (Carlsson 
et al., 2010).
Pharmacological activities 
The sdf formats of the lead compounds were 
submitted to PASS online tool (http://www.pharmaexpert.
ru/passonline/) (Poroikov et al., 2003), and then their 
probable pharmacological activities and toxicities were 
predicted.
Ligand preparation 
The chemical structure of the compounds was drawn 
using ACD/ChemSketch v.12.0 software, and the obtained 
MDL format was converted into PDB format using Open 
Bable software (O’Boyle et al., 2011). 
Pharmmapper calculations
For each lead compound, the PharmMapper server 
(http:// 59.78.96.61/pharmmapper/) (Liu et al., 2010) was 
used to identify its potential target based on its fit score. 
The lead compounds were submitted in MDL. sdf format, 
the target set was limited to human targets, and all other 
parameters were kept as default.
FIGURE 1 - Chemical structures of (1A) quercetin, (1B) astragalin and (1C) quercetin 7.
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Preparation of the target protein 
The pdb files of the identified top targets were 
obtained from protein databank (http://www.rcsb.org/
pdb/home/home.do). Then, the protein files were prepared 
by removal of all water molecules and hetero groups 
except metals. The structures of the target molecules were 
optimized and the energy was minimized using Swiss 
PDB viewer V.4.1.0 software (Guex, Peitsch, 1997). 
Metapocket 2.0 online server (http://projects.biotec.
tu-dresden.de/metapocket/index.php) was then used to 
predict the best active pocket and residues of the target 
proteins. MetaPocket 2.0 is a meta server to identify ligand 
binding sites on protein surface, metaPocket is a consensus 
method, in which the predicted binding sites from eight 
methods: LIGSITEcs, PASS, Q-SiteFinder, SURFNET, 
Fpocket, GHECOM, ConCavity and POCASA are 
combined together to improve the prediction success rate 
(Zengming et al., 2011; Bingding, 2009) 
In silico molecular docking 
Molecular docking was performed using Autodock 
4.0 software (Michel, 1999), based on Lamarckian 
Genetic Algorithm; which combines energy evaluation 
through grids of affinity potential to find the suitable 
binding position for a ligand on a given protein (Morris 
et al., 1998). Polar hydrogen atoms were added to the 
protein targets and Kollman united atomic charges were 
computed. All hydrogen atoms were added to the ligands 
before the Gastiger partial charges were assigned. The 
cocrystal ligand was removed, and the bond orders were 
checked. The target’s grid map was calculated and set 
with appropriate grid spacing to include the whole protein. 
The grid box was then allocated properly in the target 
to include the active residue in the center. The default 
docking algorithms were set in accordance with standard 
docking protocol. Finally, ten independent docking runs 
were carried out for each ligand, and results were retrieved 
as binding energies. Poses that showed lowest binding 
energies were visualized using MGL tools 1.5.6. 
RESULTS AND DISCUSSION 
Molecular parameters 
According to ‘Lipinski’s rule of five’, the lead 
compounds with poor absorption or permeation are known 
when there are more than 10 HBA, 5 HBD, the molecular 
weight is greater than 500 Da and the calculated LogP 
(CLogP) is greater than 5 (or MilogP>4.15) (Lipinski et 
al., 2001). Moreover, good bioavailability is more likely 
for compounds with rotatable bonds≤10 (nrotb) and total 
polar surface area (TPSA) of ≤140 Å (Veber et al., 2002). 
In this study; only Quercetin was predicted to have a 
high probability for good oral bioavailability where the 
calculated LogP values agreed with Lipinski’s rule of 
five. Furthermore, TPSA, total hydrogen bond count and 
the number of rotatable bonds felt within the limit ranges 
(Table I). In addition, the number of hydrogen bond 
acceptors (HBA) and hydrogen bond donors (HBD) for 
Quercetin was found to be within Lipinski’s limit range 
of 7 HBA and 5 HBD. Drug molecules of molecular 
weight less than 500 Da are easily transported, diffuse and 
absorbed as compared to heavy molecules (Srimai et al., 
2013). Case in point, Quercetin has a molecular weight 
(MW) of 302.24. Astragalin and Quercetin 7 displayed 
poor bioavailability according to Lipinski’s rule of five, 
however, that does not prevent from applying other 
methods to enhance their bioavailability given that they 
show great therapeutic benefit.
Drug ability likeliness property of quercetin, 
astragalin and quercetin 7 as GPCR ligands, ion channel 
modulators (ICM), kinase inhibitors (KI), nuclear receptor 
ligands (NRL), protease inhibitors (PI) and enzyme 
inhibitors (EI) were studied, and results were obtained as 
bioactivity scores. In this context, scores>0.00 indicate 
high activity, while scores between 0.00 to −0.5 indicate 
moderate activity and scores <−0.5 indicate inactivity 
(Paramashivam et al., 2015). The results of the present study 
demonstrated that the three leads showed high bioactivity 
scores as KI, NRL and EIs (score>0.00) with Astragalin 
and Quercetin 7 being the most active as EIs (0.41 and 0.42, 
respectively) and Quercetin being the most active as KI 
and NRL (Table II). Nuclear receptors (NRs) are important 
pharmaceutical targets because they are key regulators 
of many metabolic and inflammatory diseases, including 
diabetes, dyslipidemia, cirrhosis and fibrosis (Yang, Li, 
Li, 2014). Based on our results, quercetin, qstragalin and 
quercetin 7 could be envisioned as potential ligands for 
NRs representing interesting and promising therapeutic 
alternatives to cure relevant disorders. Considerable 
TABLE I - Physicochemical parameters of the three lead 
compounds
Lead miLogP TPSA MW HBA HBD nrotb
Quercetin 1.68 131.35 302.24 7 5 1
Astragalin 0.12 190.28 448.38 11 7 4
Quercetin 7 -0.1 210.50 464.38 12 8 4
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bioactivity against GPCR was revealed by astragalin and 
quercetin 7 (0.05 and 0.04 respectively); Quercetin, on 
the other hand, produced moderate activity (−0.06). All 
three compounds exhibited moderate activities as ion 
channel modulators (−0.19, −0.05 and −0.10, respectively). 
Moderate protease inhibition was also predicted for all three 
of them. Quercetin, astragalin and quercetin 7 were found 
active as kinase inhibitors (0.28, 0.10 and 0.15, respectively), 
and they could be used to treat diseases due to hyperactive 
protein kinases, including mutant or overexpressed kinases 
in cancer, or to modulate cell functions to overcome other 
disease drivers (Adam, Laszlo, David, 2016). In fact, a 
previous study proved that even a low concentration of 
quercetin decreased the activity of 16 kinases by more than 
80%. Quantitative video microscopy analyses revealed that 
quercetin displayed strong anti-mitotic activity, leading to 
cell death (Boly et al., 2011). In another study, quercetin 7 
was found to possess anti-inflammatory activity, inhibiting 
expression of inducible nitric oxide synthase and release of 
nitric oxide by lipopolysaccharide-stimulated RAW 264.7 
macrophages in a dose-dependent manner. Quercetin 7 
also inhibited overexpression of cyclooxygenase-2 and 
granulocyte macrophage-colony-stimulating factor (Legault 
et al., 2011).
Admet properties 
The ADMET properties of the studied leads were 
calculated using admetSAR. Blood-Brain Barrier (BBB) 
penetration, Human Intestinal Absorption (HIA), Caco-
2 cell permeability and Ames test were calculated. The 
results obtained for BBB penetrability greatly agreed with 
structures of the studied compounds. It was also found 
that all tested compounds could be absorbed by the human 
intestine, but they cannot penetrate to Caco-2 (Table III). 
Nevertheless, the tested compounds proved to be potential 
substrates for Pglycoprotein (P-gp) which effluxes drugs 
and various compounds to undergo further metabolism 
and clearance (Amin, 2013) resulting in therapeutic failure 
because the drug concentration would be lower than 
expected (Levin, 2012). Many of the human microsomal 
P450s aromatase catalyze the metabolism of a wide variety 
of compounds including xenobiotic and drugs (Ghosh et al., 
2012). Thus, inhibition of cytochrome P450 isoforms might 
cause drug-drug interactions in which co-administered drugs 
fail to be metabolized and accumulate to toxic levels (Lynch, 
Price, 2007). Notwithstanding, some of the cytochrome 
P450 isoforms could be inhibited by one or more of the 
tested compounds. Fortunately, Quercetin did not show 
any acute toxicity and mutagenic effect with respect to the 
Ames test data. Surprisingly, astragalin and quercetin 7 
were found mutagenic (Mortelmans, Zeiger, 2000) and they 
need to be administered cautiously. The different Chemical 
compounds were classified into four categories based on 
the criterion of WHO (WHO, 2010). Category I contains 
compounds with LD50 values less than or equal to 50 mg/kg. 
Category II contains compounds with LD50 values 
greater than 50mg/kg but less than 500mg/kg. Category 
III includes compounds with LD50 values greater than 
500mg/kg but less than 5000mg/kg. Category IV consisted 
of compounds with LD50 values greater than 5000mg/kg. 
Hence, quercetin is slightly hazardous while astragalin 
and quercetin 7 are unlikely to present acute hazard.
Metabolic transformations 
MetaPrint2D predictions revealed that the red 
colored hydroxyl groups for the three compounds 
represented good sites for metabolism (Figure 2). 
Metabolic transformations (Glucuronidation, Sulfation, 
Methylat ion,  Dehydroxylat ion,  Glucosidation, 
Hydroxylation, Acylation, and Phosphorylation) were 
predicted for the hydroxyl groups. Dealkylation, on the 
other hand, was proposed for the ether group.
The color highlighting an atom indicates its 
Normalized Occurrence Ratio (NOR). A high NOR 
indicates a more frequently reported site of metabolism 
in the metabolite database. Atoms are colored according 
to the likelihood of a metabolic site; High: red, Medium: 
orange, Low: green, very low is not colored, and No data: 
grey. 
PASS online server 
The chemical structure is described in PASS by 
original descriptors called Multilevel Neighborhoods 
TABLE II - Estimation of drug ability of the three lead compounds
Lead GPCR ICM KI NRL PI EI
Quercitin1 -0.06 -0.19 0.28 0.36 -0.25 0.28
Astragalin 0.05 -0.05 0.10 0.20 -0.05 0.41
Quercitin7 0.04 -0.10 0.15 0.23 -0.06 0.42
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TABLE III - ADMET properties of the three lead compounds
Model Lead compound
Absorption Quercetin Astragalin Quercetin 7
Blood-Brain Barrier BBB- BBB- BBB-
Human Intestinal Absorption HIA+ HIA+ HIA+
Caco-2 Permeability Caco2- Caco2- Caco2-
P-glycoprotein Substrate Substrate Substrate Substrate
P-glycoprotein Inhibitor Non-inhibitor Non-inhibitor Non-inhibitor
Non-inhibitor Non-inhibitor Non-inhibitor
Renal Organic Cation Transporter Non-inhibitor Non-inhibitor Non-inhibitor
Distribution and Metabolism
CYP450 2C9 Substrate Non-substrate Non-substrate Non-substrate
CYP450 2D6 Substrate Non-substrate Non-substrate Non-substrate
CYP450 3A4 Substrate Non-substrate Non-substrate Non-substrate
CYP450 1A2 Inhibitor Inhibitor Non-inhibitor Non-inhibitor
CYP450 2C9 Inhibitor Non-inhibitor Non-inhibitor Non-inhibitor
CYP450 2D6 Inhibitor Non-inhibitor Non-inhibitor Non-inhibitor
CYP450 2C19 Inhibitor Non-inhibitor Non-inhibitor Non-inhibitor
CYP450 3A4 Inhibitor Inhibitor Non-inhibitor Non-inhibitor
CYP Inhibitory Promiscuity High CYP Inhibitory 
Promiscuity
Low CYP Inhibitory 
Promiscuity
Low CYP Inhibitory 
Promiscuity
Excretion and Toxicity
Human Ether-a-go-go-Related Gene 
Inhibition
Weak inhibitor Weak inhibitor Weak inhibitor
Non-inhibitor Non-inhibitor Non-inhibitor
AMES Toxicity Non AMES toxic AMES toxic AMES toxic
Carcinogens Non-carcinogens Non-carcinogens Non-carcinogens
Fish Toxicity High FHMT High FHMT High FHMT
Tetrahymena Pyriformis Toxicity High TPT High TPT High TPT
Honey Bee Toxicity High HBT High HBT High HBT
Biodegradation Not ready biodegradable Not ready biodegradable Not ready biodegradable
Acute Oral Toxicity II III III
Carcinogenicity (Three-class) Non-required Non-required Non-required
ADMET Predicted Profile (Regression)
Absorption
Aqueous solubility (LogS) -2.9994 -2.4489 -2.4489
Caco-2 Permeability (LogPapp, cm/s) 0.2245 -0.8582 -0.8582
Toxicity
Rat Acute Toxicity (LD50, mol/kg) 3.0200 2.3869 2.3869
Fish Toxicity (pLC50, mg/L) 0.4787 1.0156 1.0156
Tetrahymena Pyriformis Toxicity  
(pIGC50, ug/L)
0.6854 0.3284 0.3284
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of Atoms (MNA). For each investigated activity, PASS 
calculates two probabilities, Pa and Pi, based on statistics 
of MNA descriptors. Pa and Pi values vary from 0.000 
to 1.000 indicating the probabilities of the compound to 
be active or inactive, respectively. Our findings revealed 
that Quercetin is a potential chlordecone reductase 
inhibitors (Pa=0.986) (Table IV). The clinically important 
chlordecone reductase belongs to a family of enzymes 
known as aldo-ketoreductases. These enzymes are 
involved in the metabolism of xenobiotics and have been 
implicated in the pathogenesis of diabetic cataracts and 
muscular dystrophy (Molowa, Andrew, Shayne, 1986). 
Nonetheless, chlordecone reductase inhibition could be 
a drawback in the sense that risk of developing prostate 
cancer is positively associated with the chlordecone 
concentration in blood (Multigner et al., 2016). Astragalin 
showed a higher probability to function as Membrane 
integrity agonist (Pa = 0.989). Thus playing an important 
role in the anti-inflammatory mechanism, Case in point, 
the results of a recent study showed that astragalin 
suppressed the expression of tumor necrosis factor α, 
interleukin 6, and nitric oxide in a dose-dependent manner 
in primary cultured mouse mammary epithelial cells (Li et 
al., 2014). Quercetin 7 on the other hand was found useful 
as hemostatic.
In silico molecular docking 
PharmMapper server has predicted that hematopoietic 
prostaglandin (PG) D synthase (HPGDS) (PDB ID: 1V40), 
Farnesyl diphosphate synthetase (FPPS) (PDB ID: 1YQ7) 
and the deoxycytidine kinase (DCK) (PDB ID: 1P60) 
are the best targets, in terms of fit scores (3.596, 3.647 
and 6.265), for quercetin, astragalin and quercetin 7, 
respectively. HPGDS is responsible for the production of 
PGD (2) as an allergy or inflammation mediator in mast 
and Th2 cells (Inoue et al., 2004). It has shown promise as 
a potential target for anti-allergic and anti-inflammatory 
drugs (Fredrik et al., 2015). Quercetin was successfully 
docked into HPGDS with a binding energy of -6.28 kcal/
mol. Analysis of the binding interactions revealed that 
quercetin formed a hydrogen bond with the active pocket 
via two residues namely Arg 412 and Lys 598 (Figure 3A). 
The above-mentioned interaction of Quercetin with the 
two amino acids results in a recognizable conformational 
change in the active pocket. Thus, the active pocket will 
no longer be complementary with the natural substrate. 
Being an HPGDS inhibitor, Quercetin can be considered 
as a potential lead for development of novel drugs 
for allergy and inflammation. As shown in Figure 3B, 
Docking of astragalin into FPPS enzyme (binding energy 
= -2.72 kcal/mol) showed hydrogen bonding with Tyr 
363, Arg 74, Asn 73, which are central binding residues 
for the top active pocket as predicted by Metapocket 2.0. 
FPPS is a key enzyme in isoprenoid biosynthesis which 
catalyzes the formation of farnesyl diphosphate (FPP), 
a precursor for several classes of essential metabolites 
including sterols, dolichols, carotenoids, and ubiquinones. 
FPP also serves as substrate for protein farnesylation 
and geranylgeranylation. Catalyzes the sequential 
TABLE IV - Prediction of biological activities of the compounds
Lead compound Pa Pi Activity
Quercetin 0.986 0.001 Chlordecone reductase inhibitor
Astragalin 0.989 0.001 Membrane integrity agonist
Quercetin 7 0.986 0.001 Hemostatic
Pa: Probability of activity. Pi: Probability of inactivity.
FIGURE 2 - Metabolic transformations of (1) quercetin, (2) 
astragalin and (3) quercetin 7.
In silico pharmacodynamics, toxicity profile and biological activities of the Saharan medicinal plant Limoniastrum feei
Braz. J. Pharm. Sci. 2017;53(3):e61 Page 7 / 10
condensation of isopentenyl pyrophosphate with the 
allylic pyrophosphates, dimethylallyl pyrophosphate, 
and then with the resultant geranylpyrophosphate to 
the ultimate product farnesyl pyrophosphate (Manoj, 
Archana, Sanjana, 2013). Recent studies have validated 
FPPS as a molecular target of bisphosphonates for drug 
development against tumors as well as human pathogens 
(Raikkonen et al., 2011; Oldfield, 2010). It appears that 
Astragalin activity could be mediated through FPPS- 
inhibition. Quercetin 7 docked nicely within the fourth 
active pocket of DCK enzyme (binding energy = -4.04 
kcal/mol). The hydrogen bonds were formed with Gln 
168, Arg 20, Gln 165, and Lys 23 (Figure 3C). It is worth 
noting that DCK is required for the phosphorylation 
of several deoxyribonucleosides and their nucleoside 
analogs. Deficiency of DCK is associated with resistance 
to antiviral and anticancer chemotherapeutic agents. 
Conversely, increased deoxycytidine kinase activity is 
associated with increased activation of these compounds 
to cytotoxic nucleoside triphosphate derivatives. DCK 
is clinically important because of its relationship to drug 
resistance and sensitivity (Hazra et al., 2011). Thus, an 
anticancer activity is predicted for quercetin 7 through 
DCK inhibition.
FIGURE 3 - The chemical interaction between the proteins and the ligands visualized using MGL tools and molecular surface (ms), 
where: (3A) HPGDS and quercetin, (3B) FPPS and astragalin, (3C) DCK and quercetin 7.
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CONCLUSION 
The ADMET profiles for the lead compounds; 
quercetin, astragalin and quercetin 7, isolated from 
Limoniastrum feei have been estimated using different web 
based in silico tools. In addition, their biological activity 
spectra were also investigated. Quercetin was proposed to 
have potential antiallergic and anti-inflammatory activity 
through inhibition of HPGDS and was also proposed 
to play a role in the treatment of diabetic cataracts and 
muscular dystrophy through inhibition of chlordecone 
reductase enzyme. Astragalin was predicted to have 
anticancer activity mediated by FPPS inhibition. While 
quercetin 7 was proposed to have an anticancer and 
antiviral activity through DCK inhibition and hemostatic 
activity as well.
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